Company profilePharmaceutical#104 of 1,318 in Pakistan✓ No DRAP alerts

Ferozsons Laboratories Limited

Pharmaceutical company · 152 brands · 126 molecules

Ranked #5 of 112 companies in Blood Glucose Lowering Drugs, Excluding Insulin

152 registered products 59 pharmaceutical brands 126 distinct molecules 0 DRAP alerts

Company overview

152
registered products
59
pharmaceutical brands
126
distinct molecules
12
therapeutic classes
0
DRAP alerts

Ferozsons Laboratories Limited is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 152 product registrations across 126 distinct molecules. It is the 104th largest registrant in Pakistan by product count, and ranks 5th of 112 in Blood Glucose Lowering Drugs, Excluding Insulin. Its portfolio is concentrated in Blood Glucose Lowering Drugs, Excluding Insulin and Antivirals For Systemic Use. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Reported financials

Publicly reported · fiscal year 2025 (ended June 30, 2025)

PKR 13.858 billion
revenue
PKR 528 million
net profit
PKR 12.15
EPS
PKR 16.937 billion
market cap

Source: company filing

Products by Ferozsons

180 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

83
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
20251
202682

Top molecules by brand count

Sofosbuvir9 brands
Metformin6 brands
Acyclovir5 brands
Aprepitant5 brands
Aciclovir4 brands
Sofosbuvir ...... 400 Mg4 brands
Ribavirin4 brands

Therapeutic classes

Blood Glucose Lowering Drugs, Excluding Insulin · 14Antivirals For Systemic Use · 12Gastro · 9Angiotensin-Ii Antagonists, Combinations · 6Antithrombotic Agents · 5Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 5Diabetes · 4Cardiac Care · 4Anti-Infectives · 3Blood Conditions · 2Immunosuppressants · 2Antiemetics & Antinauseants · 2

Conditions treated

Ulcer/Reflux/Flatulence/Acidity · 5Oral Agents · 4Hypertension · 4Blood Clot/Thrombotic Disorder · 2Probiotic · 2General Infections · 1Cold/Cough/Flu · 1Wounds/Burns/Infections · 1Intestinal & Bowel Syndrome · 1Fungal Infection · 1Hair Loss · 1Arthritis · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official100 products · Rs 37.34 – Rs 77,702.92
DVAGO53 products · Rs 77 – Rs 4,508
Servaid37 products · Rs 69.02 – Rs 1,511.92
Median across source: Rs 396.9

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

GETZ PHARMA PAKISTAN (PVT) LTD. holds 225 molecules not in this portfolio
),Formoterol3 ) 20Mg} Folic AcidAcetazolamideAdrenalineAlbendazoleAmitriptyline
CCL Pharmaceuticals (Pvt.) Ltd. holds 116 molecules not in this portfolio
3) 40Mg)Alpha KetoanaloguesAmino AcidsAmiodaroneApixabanArtemether
NABIQASIM INDUSTRIES (PVT) LTD. holds 164 molecules not in this portfolio
2 MiuAcefyllin PiperazineAcefyllineAcetaminophinAcetylsalicyclic AcidAgomelatine

Get the full profile for Ferozsons

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.